Clinical Trial Update: A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. [EARLY_Phase 1]

View source ↗

Summary

An early-phase pilot study evaluating dacomitinib with or without osimertinib in patients with metastatic EGFR-mutant non-small cell lung cancer that progressed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: EGFR Gene Mutation, Lung Cancer | EARLY_Phase 1 | Status: COMPLETED